shutterstock_399778786_paul_brady_photography

Paul Brady Photography / Shutterstock.com

9 November 2023Big PharmaMuireann Bolger

FTC challenges more than 100 pharma patents

Commission targets big pharma companies over ‘improper listings’ | Agency argues that alleged inaccuracies may delay lower-cost generic drug competition, stall drug development, and stifle innovation.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

FTC weighs in on AbbVie antitrust litigation

22 June 2023 Commission argues that a New York federal court erred in its finding that deals between an AbbVie unit and generic manufacturers were justified | US Supreme Court previously ruled that “unjustified” reverse payments can violate the antitrust laws.

FTC sues to bar Amgen from major IP $28bn acquisition

18 May 2023 The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.

More on this story

FTC weighs in on AbbVie antitrust litigation

22 June 2023 Commission argues that a New York federal court erred in its finding that deals between an AbbVie unit and generic manufacturers were justified | US Supreme Court previously ruled that “unjustified” reverse payments can violate the antitrust laws.

FTC sues to bar Amgen from major IP $28bn acquisition

18 May 2023 The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.

More on this story

FTC weighs in on AbbVie antitrust litigation

22 June 2023 Commission argues that a New York federal court erred in its finding that deals between an AbbVie unit and generic manufacturers were justified | US Supreme Court previously ruled that “unjustified” reverse payments can violate the antitrust laws.

FTC sues to bar Amgen from major IP $28bn acquisition

18 May 2023 The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims